Bioinorganic chemistry: Magnetic resonance imaging contrast agents based on iron, cobalt or nickel, CEST or T1 probes responsive to pH, or redox environment, self-assembled multinuclear iron complexes for imaging and drug delivery.
The central theme in our research is the synthesis of inorganic complexes for biomedical diagnostics, sensing, or therapeutic applications.
Current research in our laboratories focuses on the following topics:
Magnetic resonance imaging probes that are responsive to biological environment
Paramagnetic metal ion complexes are widely used in clinical medicine as contrast agents for MRI. We have developed the first examples of paramagnetic transition metal complexes that act as chemical exchange saturation transfer agents (paraCEST). ParaCEST agents produce contrast that can be turned on and off with a presaturation pulse, eliminating the need for pre- and post-contrast agent MRI scans.
Metal ions with excellent magnetic properties for paraCEST include the biologically relevant metal ions Fe(II), Co(II) and Ni(II). We have prepared macrocyclic complexes of these metal ions that are inert towards dissociation and are in high spin form. These complexes produce intense CEST contrast that is shifted far from the signal from bulk water in tissue. To further increase signal, Co(II) complexes have been incorporated into liposomes to produce lipoCEST agents. Our paraCEST agents are sensitive to temperature and to pH and are under development for mapping temperature and pH in tissue. Tuning the redox properties of the iron and cobalt complexes produces paraCEST agents that switch on and off according to redox potential. More recently, we have prepared iron based T1 agents that increase MRI signal in the presence of oxidants through Fe(II)/Fe(III) changes and Fe(III) probes that show increased relaxivity upon binding Zn(II) ions.
Iron(III) coordination complexes as alternatives to Gadolinium(II) MRI contrast agents
High spin Fe(III) complexes show great promise as contrast agents that increase relaxation of water protons for T1 weighted MRI. Our group has produced a new class of macrocyclic Fe(III) complexes that produce water proton relaxivity in serum that rivals that of clinically used Gd(III) complexes. These iron complexes do not have a rapidly exchanging water ligand, but function through second-sphere water interactions and through proton exchange.
The synthetic chemistry of the Fe(III) macrocyclic complexes is quite versatile, allowing us to change ancillary groups to tune the biodistribution and pharmacokinetics of clearance from mice. The overall charge and lipophilicity of the complexes is varied to produce a strong signal in the vasculature and for rapid renal clearance. Complexes that bind tightly to serum albumin for use as blood pool agents are also being studied. These complexes are being further developed and tested in vivo in collaboration with Roswell Park Comprehensive Cancer Center imaging scientists.
Yeast-derived Β-glucan particles (GPs) are hollow shells that act as carriers for drugs and imaging probes. The GPs are promising for targeting immune cells including macrophages and monocytes. Fe(III) complexes with open coordination sites bind strongly to GPs and are released upon treatment with mild acid or a chelator. The iron-loaded GPs are taken up by macrophages, opening up the possibility of targeting macrophages in tumors for imaging.
Coordination cages for biomedical imaging and drug delivery
An approach to further increase the signal from the paramagnetic probe involves the incorporation of multiple centers in a coordination cage. Our initial studies used the tetrahedral iron(III) cages originally developed by the Raymond group. The four rigidly-connected iron centers in the anionic cage produce a high relaxivity MRI probe. The naphthyl groups enable binding to serum albumin to give a blood pool agent that accumulates in tumors. Recent studies show that gold metallodrugs act as guests within the cage under biological conditions. These Au(I) complexes are solubilized in aqueous solution and produce a unique biodistribution upon intravenous injection in animals, including increased tumor uptake. Studies are underway to examine the theragnostic potential of these agents and new cages are under development with six metal centers.